

1 Full title: **Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque**

2
3
4
5
6 Mauricio A. Martins¹, Damien C. Tully², Young C. Shin¹, Lucas Gonzalez-Nieto¹, Kim L.
7 Weisgrau³, David J. Bean², Rujuta Gadgil², Martin J. Gutman¹, Aline Domingues¹, Helen
8 S. Maxwell¹, Diogo M. Magnani¹, Michael Ricciardi¹, Nuria Pedreño-Lopez¹, Varian
9 Bailey¹, Michael A. Cruz¹, Noemia S. Lima⁴, Myrna C. Bonaldo⁴, John D. Altman⁵, Eva
10 Rakasz³, Saverio Capuano III³, Keith A. Reimann⁶, Michael Piatak Jr.^{7†}, Jeffrey D.
11 Lifson⁷, Ronald C. Desrosiers¹, Todd M. Allen², David I. Watkins^{1#}
12
13
14
15
16
17
18
19
20
21
22

23 ¹ Department of Pathology, University of Miami, Miami, FL, USA; ² Ragon Institute of
24 MGH, MIT and Harvard, Cambridge, MA, USA; ³ Wisconsin National Primate Research
25 Center, University of Wisconsin–Madison, Madison, WI, USA; ⁴ Laboratório de Biologia
26 Molecular de Flavivirus, Instituto Oswaldo Cruz–FIOCRUZ, Rio de Janeiro, Brazil; ⁵
27 Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA;
28 ⁶ MassBiologics, University of Massachusetts Medical School, Boston, MA, USA; ⁷ AIDS
29 and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National
30 Laboratory for Cancer Research, Frederick, MD, USA.
31
32
33
34
35
36
37
38
39
40
41

42 † Deceased.

43
44 Running title: **Rare Control of SIVmac239 Replication**

45
46 # Corresponding author: David I. Watkins, dwatkins@med.miami.edu.

47
48 Address: Life Science Tech Park/Pathology, 1951 NW 7th Ave, room 2340, Miami, FL
49 33136. Phone: 305 243-0405; Fax: 305 243-7667.
50
51
52
53
54
55

56 Manuscript keywords: SIV vaccine, lymphocyte depletion, nonhuman primate, HIV/AIDS
57
58
59
60

ABSTRACT (Word count: 250; maximum: 250)

Effector memory T-cell (T_{EM}) responses display potent antiviral properties and have been linked to stringent control of simian immunodeficiency virus (SIV) replication. Since recurrent antigen stimulation drives the differentiation of $CD8^+$ T-cells toward the T_{EM} phenotype, here we incorporated a persistent herpesviral vector into a heterologous prime/boost/boost vaccine approach in order to maximize the induction of T_{EM} responses. This new regimen resulted in $CD8^+$ T_{EM} -biased responses in four rhesus macaques, three of which controlled viral replication to $<1,000$ viral RNA copies/mL of plasma for more than six months after infection with SIVmac239. Over the course of this study, we made a series of interesting observations in one of these successful controller animals. Indeed, *in vivo* elimination of $CD8\alpha\beta^+$ T-cells using a new $CD8\beta$ -depleting antibody did not abrogate virologic control in this monkey. Only after its $CD8\alpha^+$ lymphocytes were depleted did SIV rebound, suggesting that $CD8\alpha\alpha^+$ but not $CD8\alpha\beta^+$ cells were controlling viral replication. By two weeks post infection, the only SIV sequences that could be detected in this animal harbored a small in-frame deletion in *nef* affecting six amino acids. Deep sequencing of the SIVmac239 challenge stock revealed no evidence of this polymorphism. However, sequencing of the rebound virus following $CD8\alpha$ depletion at week 38.4 post infection again revealed only the six-amino acid deletion in *nef*. While any role for immunological pressure on the selection of this deleted variant remains uncertain, our data provide anecdotal evidence that control of SIV replication can be maintained without an intact $CD8\alpha\beta^+$ T-cell compartment.

INTRODUCTION

The rationale for engendering HIV-specific CD8⁺ T-cell responses by vaccination comes from a wealth of data indicating that cellular immunity can limit viral replication *in vivo*.¹⁻⁵ While eliciting efficacious CD8⁺ T-cells against this virus has not been straightforward, as evidenced by the failures in clinical trials of all HIV-1 vaccine regimens aimed at inducing CD8⁺ T-cell responses tested to date,⁶⁻⁸ valuable insights have been gained from the SIV/rhesus macaque model. For example, live-attenuated SIV vaccines have consistently afforded the greatest levels of efficacy against challenge with the pathogenic SIVmac239 clone.^{9, 10} Although protection in these cases is likely multifactorial, Fukazawa *et al.* have recently shown that the magnitude of effector-differentiated T-cell responses in lymph nodes of vaccinated macaques correlates with the efficacy of live-attenuated SIV vaccines.¹⁰ Importantly, the maintenance of these protective SIV-specific T-cells correlated with the ability of live-attenuated SIV vaccines to persistently replicate at low levels in lymph nodes. By comparison, the majority of HIV/SIV vaccine platforms tested to date consist of weakened or replication-defective vectors that provide only transient antigen (Ag) exposure.¹¹⁻¹⁴ Although T-cell responses elicited by these conventional vector platforms have often exhibited satisfactory immunogenicity profiles, their performance in stringent SIV challenge trials has varied considerably, ranging from no protection to partial virologic control.¹⁵⁻¹⁹ Given the superior outcomes achieved with live-attenuated SIV vaccines, regimens that safely provide recurrent low-level exposure to viral proteins might facilitate the induction of effective anti-lentiviral T-cell immunity.

Herpesviruses establish latent infections that persist for the life of the host.²⁰ Similar to live-attenuated SIV vaccination, herpes viral infections result in persistent Ag

1 stimulation, which favors the induction of effector memory T-cell (T_{EM}) responses.²¹ This
2 phenotype is associated with T-cells that recirculate through extralymphoid tissues and
3 are poised for immediate antiviral activity.²² The persistent nature of herpesviruses and
4 the antiviral properties of T_{EM} prompted the generation of live recombinant (r)
5 herpesviral vectors encoding SIV proteins. For example, a fibroblast-adapted strain of
6 the β -herpesvirus rhesus cytomegalovirus (RhCMV) expressing SIV inserts has shown
7 great promise in monkey trials with approximately half of RhCMV/SIV vaccinees
8 manifesting early and profound control of viral replication after SIVmac239 infection.^{23, 24}
9 Remarkably, these protected vaccinees eventually cleared SIV *in vivo*, implying that
10 lentiviral infections are vulnerable to early interception by vaccine-induced T_{EM}
11 responses.²⁵ Importantly, RhCMV is not the only herpesviral vector platform available
12 for persistent antigen delivery in nonhuman primates. In fact, a genetic system for the
13 γ 2-herpesvirus rhesus monkey rhadinovirus (RRV) has also been developed,²⁶
14 facilitating the generation of rRRV/SIV vectors.²⁷ In contrast to the unconventionally
15 major histocompatibility complex (MHC)-restricted $CD8^+$ T_{EM} responses elicited by the
16 aforementioned RhCMV strain,^{28, 29} rRRV/SIV-vaccinated macaques develop $CD8^+$ T-
17 cells capable of recognizing classically immunodominant MHC class I-restricted SIV
18 epitopes.²⁷ Following intravenous challenge with SIVmac239, rRRV/SIV vaccinees
19 manifested significant reductions in peak and setpoint viremia compared to
20 unvaccinated controls. Collectively, these data highlight the utility of herpesviral vectors
21 for eliciting lentivirus-specific T_{EM} responses.

22 Repeated Ag stimulation delivered in the form of heterologous prime/boost/boost
23 (PBB) immunization protocols has been shown to generate robust $CD8^+$ T_{EM} responses
24 in mice.^{30, 31} Similarly, we have recently shown that a rDNA prime followed by boosting
25 with rYF17D and rAd5 resulted in high frequency SIV-specific T_{EM} responses in rhesus
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 macaques.³² However, these vaccine-induced CD8⁺ T-cells underwent considerable
2 contraction soon after the rAd5 boost, possibly due to the lack of persistent Ag
3 stimulation afforded by the rDNA/rYF17D/rAd5 protocol. In an attempt to improve the
4 maintenance of CD8⁺ T_{EM} responses, we delivered a final rRRV/SIV boost to four
5 rhesus macaques that had been immunized with a rDNA prime followed by a rYF17D
6 boost. In addition to evaluating the immunogenicity and efficacy of this new
7 rDNA/rYF17D/rRRV regimen, this pilot study resulted in an extraordinary outcome in
8 one of the vaccinated monkeys. Using viral sequencing and selective depletions of
9 CD8β- or CD8α-expressing lymphocytes *in vivo*, we investigated immunological and
10 virologic aspects of this rare case of control of SIVmac239 replication.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MATERIALS AND METHODS

Research Animals

The four Indian rhesus macaques used in the vaccine pilot study described in Figure 1 were naturally infected with RRV. The two SIV-infected Indian rhesus macaques used in the experiment described in Figure 4 were part of a recent study conducted by our laboratory and were used to further characterize the effects of CD8 β depletion during controlled SIV infection. All animals were housed at the Wisconsin National Primate Research Center (WNPRC) and cared for in accordance with the Weatherall Report under a protocol approved by the University of Wisconsin Graduate School Animal Care and Use Committee. Vaccinations, SIV challenges, and monoclonal antibody (mAb) infusions were performed under anesthesia and all efforts were made to minimize potential suffering. Additional animal information, including MHC class I alleles, age, and sex, is shown in Table 1.

Vaccinations

The macaques in Groups 1 and 2 were primed once with rDNA plasmids expressing SIVmac239 minigenes encoding Nef amino acids (aa) 45-210 (Group 1) or Gag aa 178-258 (Group 2). One milligram of each rDNA/SIV vector and 0.1 mg of an IL-12-expressing plasmid were co-delivered by intramuscular electroporation. The monkeys then received 300,000 plaque-forming units of rYF17D vectors encoding the same inserts as the rDNA plasmids via the subcutaneous route. Additional information on the rDNA and rYF17D vaccinations can be found elsewhere.³³ The third and last vaccine boost consisted of a single infusion of 1.0 mL of phosphate-buffered saline (PBS) solution containing 7.0×10^8 genome copies of rRRV vectors encoding

1 SIVmac239 inserts. Animals in Group 1 received rRRV/*rev-tat-nef* while those in Group
2 2 were vaccinated with rRRV/*gag* (Fig. 1A). The construction of these rRRV/SIV
3
4
5
6
7 vaccines has been described elsewhere.²⁷
8
9

10 11 *SIVmac239 challenges*

12
13
14
15
16 The challenge stock utilized here was produced by the Virology Services Unit of
17 the WNPRC using SIVmac239 hemi-genome plasmids obtained from the NIH AIDS
18 Research and Reference Reagent Program. These plasmids were transfected into 293T
19 cells and the supernatant was propagated on mitogen-activated PBMC from SIV naïve
20 rhesus macaques for several days. The titer of this stock was 90,000 50% tissue culture
21 infective doses (TCID₅₀)/mL. Animals in this study were subjected to the same weekly
22 intrarectal (IR) SIVmac239 challenge regimen described recently.³² The dose of each
23 exposure was 200 TCID₅₀, which corresponded to 4.8×10⁵ viral RNA (vRNA) copies.
24 Plasma viral loads (VLs) were assessed three and seven days after each exposure.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Once an animal had a positive VL, it was no longer challenged.

41 42 *In vivo* CD8 depletions

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CD8β-expressing lymphocytes were transiently depleted using the anti-CD8β
mAb CD8β255R1. The parental mouse mAb was raised against rhesus CD8β chain and
engineered into a recombinant rhesus IgG1 by complementarity-determining region
(CDR) grafting. CD8α⁺ cells were depleted using a CDR-grafted rhesus IgG1,
MT807R1, derived from a mouse anti-human CD8α mAb.³⁴ All animals were
administered a single intravenous injection of 50 mg/kg of body weight. Both mAbs were
provided by the NIH Nonhuman Primate Reagent Resource (Boston, MA).

MHC class I tetramer staining and immunophenotyping during lymphocyte depletions

We monitored the ontogeny of vaccine-induced SIV-specific CD8⁺ T-cell responses in Groups 1 and 2 using fluorochrome-labeled MHC class I tetramers, as described recently.³⁵ In sum, peripheral blood mononuclear cells (PBMC) were isolated from blood drawn at the WNPRC on the previous day and then shipped to the University of Miami overnight. We used allophycocyanin-conjugated Mamu-B*08/Nef₁₃₇₋₁₄₆RL10 (NIH Tetramer Core Facility) and Mamu-A*01/Gag₁₈₁₋₁₈₉CM9 (MBL International) tetramers to monitor vaccine-induced SIV-specific CD8⁺ T-cell responses in the Group 1 and Group 2 macaques, respectively. Up to 800,000 PBMC were incubated with titrated amounts of each tetramer at 37°C for one hour and then stained with fluorochrome-labeled antibodies directed against the surface molecules CD3 (clone SP34-2), CD8α (clone RPA-T8), CD28 (clone 28.2), CCR7 (clone 150503), CD14 (clone M5E2), CD16 (clone 3G8), and CD20 (clone 2H7). Amine-reactive dye (ARD; Live/DEAD Fixable Aqua Dead Cell Stain; Life Technologies) was also added to this mAb cocktail. After a 25-min incubation at room temperature (RT), the cells were washed with Wash Buffer (Dulbecco's PBS with 0.1% bovine serum albumin and 0.45 g/L NaN₃) and then fixed with PBS containing 2% of paraformaldehyde. The configuration of the Special Order Product BD LSR II cytometer used to acquire the samples and the gating strategy employed to analyze the data have been detailed elsewhere.³² In sum, we used FlowJo 9.6 to determine the percentages of live CD14⁻CD16⁻CD20⁻ CD3⁺CD8⁺tetramer⁺ lymphocytes displayed on Figure 1B & C and to delineate memory subsets within tetramer⁺ populations (Fig. 1D & E).

To monitor the frequencies of lymphocyte subsets during the CD8β and CD8α depletions, our surface staining master mix included the same clones of anti-CD3, anti-

1 CD14, anti-CD16, and anti-CD20 antibodies and the same ARD reagent mentioned
2 above. Additionally, this cocktail included antibodies against the CD8 α chain (clone SK1
3 for the CD8 β depletion phase or clone DK25 for the CD8 α depletion phase) and the
4 CD8 $\alpha\beta$ heterodimer (clone 2ST8-5H7). This latter clone recognizes a conformational
5 epitope consisting of domains from both the CD8 α and CD8 β chains.³⁶ Of note, the CD8
6 glycoprotein can be expressed as two isoforms: CD8 $\alpha\beta$ heterodimers or CD8 $\alpha\alpha$
7 homodimers.³⁷ The anti-CD8 α mAb MT807R1 that was used to deplete CD8 α^+
8 lymphocytes *in vivo* is known to cross-block other anti-CD8 antibodies used for
9 immunophenotyping. However, the anti-CD8 α clone DK25 can still resolve CD8 α^+ cells
10 in the presence of MT807R1, albeit with reduced fluorescence intensity.³⁴ In quality
11 assessment tests performed in our laboratory, we found that pre-incubation of PBMC
12 with 50 $\mu\text{g}/\text{mL}$ of the anti-CD8 β mAb CD8 β 255R1 did not prevent fluorochrome-labeled
13 2ST8-5H7 antibodies from detecting CD8 $\alpha\beta^+$ T-cells, although there was a slight
14 reduction in fluorescence intensity (data not shown). In contrast, pre-incubation of
15 PBMC with 50 $\mu\text{g}/\text{mL}$ of MT807R1 completely blocked staining with 2ST8-5H7. During
16 the CD8 β depletion phase, CD3 $^+$ T-lymphocytes that were positive for CD8 α but
17 negative for CD8 $\alpha\beta$ were considered to be CD8 $\alpha\alpha^+$. To obtain relative frequencies of
18 lymphocyte subsets, we first excluded monocytes, B-cells, and dead cells in the “dump
19 gate” (CD14 $^+$ CD20 $^+$ ARD $^+$) and then determined the percentages of CD8 $\alpha\beta^+$ T-cells
20 (CD3 $^+$ CD8 $\alpha\alpha^-$ CD8 $\alpha\beta^+$), CD8 $\alpha\alpha^+$ T-cells (CD3 $^+$ CD8 $\alpha\alpha^+$ CD8 $\alpha\beta^-$), CD4 $^+$ T-cells
21 (considered as CD3 $^+$ CD8 $\alpha\alpha^-$ CD8 $\alpha\beta^-$), and NK cells (CD3 $^-$ CD8 $\alpha\alpha^+$ CD16 $^+$) within the
22 lymphocyte gate. Absolute counts of these subsets were then calculated by multiplying
23 their respective frequencies by the absolute number of white blood cells obtained from
24 matching complete blood counts.

Intracellular cytokine staining (ICS) assay

The ICS assay was performed as described recently.³² In sum, cells were stimulated with SIV peptides at a final concentration of 1.0 μ M in the presence of co-stimulatory mAbs against CD28 (clone L293; BD Biosciences) and CD49d (clone 9F10; BD Pharmingen) for 9 h at 37 °C in a 5.0% CO₂ incubator. To inhibit protein transport, Brefeldin A (Biolegend, Inc.) and GolgiStop (BD Biosciences) were added to all tubes 1 h into the incubation period. We employed the same steps outlined above to stain molecules on the surface of cells and to fix them with 2% of paraformaldehyde. In addition to the same mAbs against CD14, CD16, and CD20 and the ARD reagent described above, the surface staining master mix also included mAbs against CD4 (clone OKT4; Biolegend, Inc.) and CD8 (clone RPA-T8; Biolegend, Inc.). Cells were permeabilized by resuspending them in “Perm Buffer” (1 \times BD FACS lysing solution 2 [Beckton Dickinson] and 0.05% Tween 20 [Sigma-Aldrich]) for 10 min and subsequently washed with Wash Buffer. Cells were then incubated with mAbs against IFN- γ (clone 4S.B3; Biolegend, Inc.), TNF- α (clone Mab11; BD Biosciences), and CD3 (same one mentioned above) for 1 h in the dark at RT, washed, and subsequently stored at 4 °C until acquisition.

Anti-immunoglobulin (Ig) ELISA

ELISA plates (Nunc-Immuno) were coated overnight at 4°C with either MT807R1 or CD8 β 255R1. All subsequent steps and incubations were performed at RT. On the following day, plates were washed five times with Wash Buffer (PBS containing 0.05% of Tween 20) and then blocked with SuperBlock buffer (Thermo Scientific) for 15 min. Plasma from r04132 and r08019 collected 8 days prior to (pre-depletion) or 22 days after (post-depletion) the anti-CD8 β mAb infusion was used in this assay. Plasma from

1 untreated or anti-CD8 α -treated monkeys was used as negative and positive controls,
2
3 respectively. After diluting plasma samples 10-fold in PBS containing 2% of bovine
4
5 serum albumin, these aliquots were serially diluted 1:4 until a dilution factor of 10,240
6
7 was achieved. One hundred μ L of these serially diluted plasma aliquots were added to
8
9 plates, followed by a 1-h incubation. Subsequently, plates were washed 5 times and
10
11 100 μ L of a 100-fold dilution of anti-Ig human λ light chain-conjugated to biotin (Miltenyi
12
13 Biotec) were added to each well and incubated for one hour. Plates were then washed
14
15 five times before 100 μ L of a 10,000-fold dilution of horseradish peroxidase-conjugated
16
17 Streptavidin (Invitrogen) were added to each well. After a 1-h incubation, plates were
18
19 washed five times. One hundred μ L of TMB (Calbiochem) were added to the plates for
20
21 approximately 3 min and then the substrate reaction was stopped with H₂SO₄ Stop
22
23 Solution (Southern Biotech). The optical density (OD) of each well was determined on
24
25 an ELISA reader using a 450-nm filter. Endpoint titers of anti-Ig antibodies were
26
27 considered as the highest dilutions where the OD of the post-depletion sample was >2-
28
29 fold higher than its pre-depletion counterpart.
30
31
32
33
34
35
36
37
38
39

40 *SIV viral load measurements*

41
42 VLs were measured using 0.5 mL of EDTA-anticoagulated plasma based on a
43
44 modification of a previously published protocol.³⁸ Total RNA was extracted from plasma
45
46 samples using QIAgen DSP virus/pathogen Midi kits, on a QIASymphonyXP laboratory
47
48 automation instrument platform. Six replicate two step RT-PCR reactions were
49
50 performed per sample using a random primed reverse transcription reaction, followed
51
52 by 45 cycles of PCR using the following primers and probe: forward primer: SGAG21:
53
54 5'-GTCTGCGTCAT(dP)TGGTGCATTC-3'; reverse primer SGAG22: 5'-
55
56 CACTAG(dK)TGTCTCTGCACTAT(dP)TGTTTTG-3'; probe: PSGAG23: 5'-FAM-
57
58
59
60

CTTC(dP)TCAGT(dK)TGTTTCACTTTCTCTTCTGCG-BHQ1-3'. The limit of reliable quantitation on an input volume of 0.5 mL of plasma was 15 vRNA copies/mL.

Whole-genome deep sequencing of SIVmac239

Viral RNA in plasma was isolated using the QIAamp viral RNA mini kit (Qiagen), according to the manufacturer's protocol, and eluted in 60 µl of AVE buffer. The eluate was then aliquoted and stored at -80°C for future use. Viral RNA was reverse transcribed and amplified by using the SuperScript III One-Step RT-PCR system with High Fidelity Platinum Taq polymerase (Invitrogen). PBMCs from rhesus macaque were washed twice with PBS and DNA was then extracted from the cells using the QiAMP DNA Blood Mini Kit (Qiagen) with PCR amplifications performed as described below with the exception of the first RT step. For the r08019 wk 38.4 PI sample, a near full-length genome of SIV was amplified in four segments using the following primers:

Amp1-F (5'-AGGAACCAACCACGACGGAG-3') and Amp1-R (5'-AAAGGGATTGGCACTGGTGCGAGG-3'); Amp2-F (5'-TGCTGACGGCTTGTC AAGGAGTAGG-3') and Amp2-R (5'-ACCCTGTCATGTTCCAGGTCTGTCC-3'); Amp3-F (5'-ATGGTGGGCAGGGATAGAGC-3') and Amp3-R (5'-CCATGCCTGCTTTGGCCTAT-3'); Amp4-F (5'-TGCACAGGCTTGGAACAAGA-3') and Amp4-R (5'-ACATCCCCTTGTGGAAAGTC-3'). The RT-PCR conditions were as follows for Amp 1 and 2: 50 °C for 30 min; 94 °C for 2 min; 40 cycles of 94 °C for 15 sec, 55 °C for 30 sec, and 68 °C for 3 min; and for Amp 3 and 4: 45 °C for 120 min, 94 °C for 15 sec; 40 cycles of 94 °C for 15 sec, 50 °C for 30 sec, and 68 °C for 6 min; and 68 °C for 6 min. In the case of PBMC from r08019 collected at wk 2 PI, only one amplicon was successfully amplified and sequenced, despite multiple attempts using different

1 primer sets and conditions. A 2.4-kb fragment spanning part of *env* and *nef* (positions
2 7,565-9,979) amplified using forward primer (5'-CAGTCACCATTATGTCTGGATTG-3')
3
4 and reverse primer (5'-GAATACAGAGCGAAATGCAGTG-3') under the conditions
5
6 detailed above for amp 1 and 2. A smaller amplicon-based 454 sequencing approach
7
8 was used to analyze a 400-bp region in Nef as previously described.³⁹ Whole genome
9
10 deep sequencing was also performed on the SIVmac239 challenge as previously
11
12 described.⁴⁰
13
14
15
16
17
18

19 Amplicons were visualized on a 1.0% agarose gel and purified using the Purelink
20 quick gel extraction kit (Invitrogen). RT-PCR products were quantified using a Promega
21 quantiflor-ST fluorometer (Promega) and analyzed for quality using an Agilent 2100
22 bioanalyzer with high sensitivity DNA chips. PCR amplicons were fragmented and
23 barcoded using NexteraXT DNA Library Prep Kit, as per manufacturer's protocol.
24 Samples were pooled and sequenced on an Illumina MiSeq platform, using a 2 x 250-
25 bp V2 reagent kit. Paired-end reads obtained from Illumina MiSeq were assembled into
26 a SIV consensus sequence using the VICUNA *de novo* assembler software and finished
27 with V-FAT v1.0.⁴¹ Reads were mapped back to this consensus using Mosaik v2.1.73,
28 and intra-host variants called by V-Phaser v2.0.^{42, 43} All reads have been deposited to
29 the NCBI Sequence Read Archive under accession number SRP016012.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Four rhesus macaques were equally divided between two groups based on their MHC class I alleles: monkeys in Group 1 were *Mamu-B*08*⁺ and those in Group 2 were *Mamu-A*01*⁺ (Fig. 1A). We chose these MHC class I alleles because their gene products present immunodominant SIV epitopes. Specifically, *Mamu-B*08* binds to Nef₁₃₇₋₁₄₆RL10 while *Mamu-A*01* restricts Gag₁₈₁₋₁₈₉CM9.^{44, 45} Of note, expression of *Mamu-B*08* has been linked to elite control of SIVmac239 infection.⁴⁶

To achieve the continual Ag stimulation that favors induction of T_{EM} responses,^{21, 47} we combined the repetitive boosting provided by heterologous PBB regimens and the persistent Ag exposure afforded by herpesviral infections into a new immunization protocol. This protocol consisted of successive vaccinations with electroporated rDNA, rYF17D, and rRRV vectors encoding SIVmac239 inserts (Fig. 1A). The vectors employed in Group 1 and Group 2 delivered the Nef₁₃₇₋₁₄₆RL10 and Gag₁₈₁₋₁₈₉CM9 epitopes, respectively, to match the expressed MHC class I alleles (Fig. 1A). To monitor the ontogeny of vaccine-induced CD8⁺ T-cell responses against each epitope, we performed longitudinal fluorochrome-labeled MHC class I tetramer stainings in PBMC from the Group 1 and Group 2 animals. The two *Mamu-B*08*⁺ vaccinees developed low frequency responses against Nef₁₃₇₋₁₄₆RL10, with percentages of tetramer⁺CD8⁺ T-cells peaking at 4% and then decreasing to <1% of CD8⁺ T-cells by wk 34 post rYF17D (Fig. 1B). Conversely, both *Mamu-A*01*⁺ animals in Group 2 mounted robust Gag₁₈₁₋₁₈₉CM9-specific CD8⁺ T-cells after the rRRV boost (14% and 16% at peak; Fig. 1C). While the magnitude of these tetramer⁺CD8⁺ T-cells eventually declined to <1% in r01049, the other Group 2 vaccinee (r08019) maintained its Gag₁₈₁₋₁₈₉CM9-specific response at 4.6% after resolution of the peak response (Fig. 1C). It is not entirely clear why the

1 contraction of vaccine-induced SIV-specific CD8⁺ T-cells was accentuated in both
2 Group 1 animals and in r01049 in the weeks following the rRRV boost. Given that
3
4
5
6 captive rhesus monkeys can be naturally infected with RRV,^{48, 49} pre-existing immunity
7
8 to this herpesvirus may have limited the “take” of the live rRRV vectors utilized here.
9
10
11 Indeed, all four monkeys in Groups 1 and 2 were seropositive for RRV at the time of the
12
13
14 rRRV vaccination (data not shown).

15
16 We also carried out a phenotypic analysis of vaccine-induced SIV-specific CD8⁺
17
18 T-cells at wk 34 post rYF17D and found a predominance of the fully differentiated T_{EM2}
19
20 (CD28⁻CCR7⁻) phenotype (Fig. 1D & E), indicative of persistent Ag stimulation.
21
22 Transitional memory (T_{EM1}; CD28⁺CCR7⁻) and central memory (T_{CM}; CD28⁺CCR7⁺)
23
24 tetramer⁺CD8⁺ T-cells were also detected, especially in the Group 1 vaccinee r04132
25
26 (Fig. 1D). In sum, while 3/4 vaccinees had low frequencies of SIV-specific CD8⁺ T-cells
27
28 at the time of SIV challenge, r08019 was clearly an outlier since >4% of its peripheral
29
30
31 CD8⁺ T-cell compartment was specific for a single SIV epitope and 96% of these
32
33
34 exhibited the T_{EM2} phenotype.
35
36

37
38 At wk 19 post rRRV boost, we began challenging all animals intrarectally with
39
40 200 TCID₅₀ of an *in vivo*-titrated SIVmac239 stock. Of note, out of the 32 SIV naïve
41
42 rhesus macaques that have been subjected to this IR challenge regimen (same viral
43
44 stock and dose) as part of ongoing experiments conducted by our group, 78% became
45
46 infected by the 6th exposure (Martins *et al.*, unpublished observations). Remarkably,
47
48 after becoming infected after the 9th IR challenge (Fig. 1F), the Group 2 vaccinee
49
50 r08019 experienced a peak VL of only 1,000 vRNA copies/mL of plasma and
51
52 subsequently controlled viremia to <15 vRNA copies/mL by wk 5 post infection (PI; Fig.
53
54
55 1G). In contrast, the other Group 2 animal (r01049) became infected after the 5th
56
57
58 challenge and failed to suppress viremia (Fig. 1F & G). Encouragingly, both Group 1
59
60

1 vaccinees had relatively low peak VLs and controlled chronic phase VLs to <1,000
2 vRNA copies/mL (Fig. 1G). As a reference, we compared VLs in Groups 1 and 2 with
3 those from MHC class I-matched macaques that were rectally infected with SIVmac239
4 as part of previous and ongoing studies conducted by our laboratory (Martins *et al.*,
5 unpublished observations).^{32, 33, 39} These historical controls included both unvaccinated
6 and vaccinated monkeys (Fig. 2). Overall, the two Group 1 vaccinees experienced lower
7 peak and setpoint VLs than the majority of their *Mamu-B*08*⁺ historical counterparts
8 while r08019 exhibited the lowest levels of viremia among our cohort of *Mamu-A*01*⁺
9 historical controls (Fig. 2). Thus, a rDNA/rYF17D/rRRV regimen encoding
10 immunodominant SIV epitopes resulted in stringent control of SIVmac239 replication in
11 3/4 vaccinees.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27
28 Given r08019's remarkable outcome, we then explored several potential
29 mechanisms for the impressive virologic control observed in this animal. First, we
30 postulated that this animal's robust vaccine-induced SIV-specific CD8⁺ T-cell response
31 was responsible for containing viral replication. Based on this assumption and on our
32 previous experimental data,² we expected r08019 to transiently lose control of SIV
33 replication following infusion of a CD8-depleting mAb. Of interest, the CD8 glycoprotein
34 can be expressed as two isoforms: either as a heterodimer consisting of the CD8 α and
35 CD8 β chains (CD8 $\alpha\beta$) or as a CD8 $\alpha\alpha$ homodimer.³⁷ While CD8 $\alpha\beta$ marks thymus-
36 selected MHC class I-restricted T-cells,^{37, 50} CD8 $\alpha\alpha$ is found primarily on mucosal T-
37 cells and, in the case of rhesus macaques, NK cells as well.^{51, 52} Historically, *in vivo*
38 depletion of CD8⁺ lymphocytes in SIV-infected rhesus macaques has been
39 accomplished by the infusion of antibodies specific for the CD8 α chain.^{5, 53, 54} An
40 important caveat of this approach is the simultaneous elimination of CD8 $\alpha\beta$ ⁺ T-cells and
41 NK cells, which makes it difficult to distinguish the contribution of each lymphocyte
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 subset to control of SIV infection. To avoid this limitation, we used a newly available
2 rhesus recombinant CDR-grafted mAb (CD8 β 255R1) specific for the CD8 β chain to
3 selectively ablate CD8 $\alpha\beta$ ⁺ T-cells in r08019 and in both Group 1 macaques (Fig. 3A).
4 Importantly, quality assessment tests performed prior to the CD8 β depletion confirmed
5 that CD8 β 255R1 did not block the fluorochrome-labeled anti-CD8 antibodies utilized in
6 our immunophenotyping assays (see Materials and Methods). A single infusion of 50
7 mg/kg of CD8 β 255R1 readily depleted the majority of peripheral CD8 $\alpha\beta$ ⁺ T-cells in all
8 three animals without eliminating NK cells (Fig. 3B & C). In fact, NK cell numbers
9 steadily increased following the CD8 β 255R1 infusion and peaked at wk 9 post CD8 β
10 depletion (Fig. 3C). Absolute counts of CD8 $\alpha\beta$ ⁺ T-cells also rose during this period,
11 especially in r07032 (Fig. 3D). CD4⁺ T-lymphocyte counts went up as well (Fig. 3E),
12 possibly due to the homeostatic expansion of memory CD4⁺ T-cells that occurs in
13 response to CD8 depletion *in vivo*.⁵⁵ Similar to previous CD8 α depletion studies in SIV-
14 infected elite controller macaques,² elimination of CD8 $\alpha\beta$ ⁺ T-cells in the Group 1
15 animals resulted in a transient increase in viremia (Fig. 3F). While r04132 promptly
16 reasserted control of viral replication, VLs in r07032 remained higher than their baseline
17 levels for several weeks after the CD8 β depletion (Fig. 3F). Interestingly, the rise in
18 absolute counts of CD8 $\alpha\beta$ ⁺ T-cells and NK cells coincided with decreases in viremia in
19 the *Mamu-B*08*⁺ Group 1 macaques (Fig. 3C, D, & F), implying that these CD8 $\alpha\beta$ -
20 expressing lymphocytes contributed to restoring virologic control in those animals.
21 Strikingly, except for borderline VLs (up to 30 vRNA copies/mL) shortly after the CD8 β
22 depletion, r08019 did not lose control of SIV replication and had undetectable viremia by
23 wk 4.4 post CD8 β depletion (Fig. 3F). Small increases in SIV-producing cells in lymph
24 nodes were also observed in r08019 following depletion of its CD8 $\alpha\beta$ ⁺ T-lymphocytes,
25 as determined by *in situ* hybridization performed on biopsies collected before and after
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 the mAb infusion (data not shown). This strange result suggested that an intact CD8 $\alpha\beta$ ⁺
2
3
4 T-cell compartment was not necessary for suppressing SIVmac239 replication in
5
6
7 r08019.

8
9 To determine if the ability of r08019 to maintain control of viral replication in the
10
11 context of CD8 $\alpha\beta$ ⁺ T-cell deficiency could be manifested by other macaques with
12
13 controlled SIV viremia, we subjected two additional animals to the same CD8 β depletion
14
15 regimen described above (Fig. 4). Macaques r09089 and r09037 (Group 3) expressed
16
17 *Mamu-B*08*⁺ and both controlled SIVmac239 replication as part of a recent experiment
18
19 conducted by our laboratory (Table 1).³² As described above, a single infusion of the
20
21 CD8 β 255R1 mAb resulted in near complete elimination of peripheral CD8 $\alpha\beta$ ⁺ T-cells
22
23 and a rise in NK cell counts in both r09089 and r09037, but especially in the former
24
25 animal (Fig. 4A & B). Fluctuations in absolute counts of CD4⁺ T-cells and a modest
26
27 increase in CD8 $\alpha\beta$ ⁺ T-cell numbers also ensued from the anti-CD8 β mAb treatment (Fig.
28
29 4 D & E). In contrast to r08019, but similar to the Group 1 macaques, both Group 3
30
31 macaques experienced a surge in viremia after depletion of their CD8 $\alpha\beta$ ⁺ T-cells (Fig.
32
33 4F). Although r09037 transiently regained control of viral replication at wk 4 post
34
35 treatment, SIV rebounded again shortly thereafter and VLs eventually leveled off at 100-
36
37 1,000 vRNA copies/mL (Fig. 4F). Monkey r09089 never reasserted full control of viral
38
39 replication and its VLs ultimately plateaued in the same range as of r09037 (Fig. 4F).
40
41 These results indicated that the lack of SIV rebound manifested by r08019 in the
42
43 context of CD8 $\alpha\beta$ ⁺ T-cell deficiency was not a general feature of controlled SIV
44
45 infection.
46
47
48
49
50
51
52
53

54 Next, we set out to explore whether CD8 $\alpha\alpha$ -expressing cells prevented SIV
55
56 rebound in r08019 when its CD8 $\alpha\beta$ ⁺ T-cells were eliminated. To address this possibility,
57
58 we planned to treat r08019 and r04132 with the mouse/rhesus CDR-grafted anti-CD8 α
59
60

1 mAb MT807R1 at wk 10 post CD8 β depletion. We decided not to subject r07032 to this
2 procedure since this animal had experienced adverse events during the CD8 β 255R1
3 infusion. A potential risk of this experiment was the development of anaphylactic
4 reactions triggered by anti-CD8 β 255R1 antibodies reacting against the MT807R1 Ig
5 molecule. To estimate the levels of these cross-reactive anti-Ig responses, we coated
6 ELISA plates with either CD8 β 255R1 or MT807R1 and screened pre- and post-CD8 β
7 depletion plasma for the presence of anti-Ig antibodies. The goal of this assay was to
8 determine the highest plasma dilution where the OD value of the post-depletion sample
9 was >2-fold higher than the corresponding pre-depletion sample (i.e. the endpoint titer).
10 As expected, both r04132 and r08019 developed anti-CD8 β 255R1 antibodies after the
11 CD8 β depletion, with endpoint titers of 2,560 and 160, respectively (Fig. 5). However,
12 we could not determine the endpoint titer of cross-reactive anti-MT807R1 antibodies in
13 these monkeys since their pre- and post-CD8 β depletion plasma samples yielded
14 largely equivalent OD values, even at the lowest dilution (1:10) tested (Fig. 5). Since
15 these data suggested that r08019 and r04132 had little or no anti-MT807R1 antibodies,
16 we decided to proceed with the CD8 α depletion.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Even though we could not detect anti-MT807R1 antibodies in r08019, this animal
40 experienced decreased oxygen saturation, abnormal heart rates, and vomiting during
41 the MT807R1 infusion. Monkey r08019 recovered after receiving supportive care but
42 ended up being treated with half of the planned dose of MT807R1. Conversely, r04132
43 did not experience any adverse reactions and received the full dose of MT807R1.
44 Although we administered only half of the desired amount of the anti-CD8 α mAb to
45 r08019, this dose was sufficient to transiently eliminate peripheral CD8 α -expressing
46 (CD8 $\alpha\alpha^+$ and CD8 $\alpha\beta^+$) T-lymphocytes and NK cells in this animal (Fig. 3B-D). Strikingly,
47 SIV swiftly rebounded in r08019, peaking at 190,000 vRNA copies/mL on day 11 post
48
49
50
51
52
53
54
55
56
57
58
59
60

1 CD8 α depletion (wk 38.4 PI; Fig. 3F). Macaque r04132 also experienced a brief rise in
2 viremia that peaked at 9,900 vRNA copies/mL (Fig. 3F). Both animals regained control
3 of viral replication in the ensuing weeks, concomitant with increases in absolute
4 numbers of peripheral CD8 α ⁺ T-cells and NK cells (Fig. 3C, D, & F). CD4⁺ T-
5 lymphocytes also expanded during this period, likely as a result of the CD8 α depletion
6 (Fig. 3E). These data suggested that effector lymphocytes expressing CD8 α
7 homodimers, but not CD8 α β heterodimers, were responsible for maintaining virologic
8 control in r08019.
9
10
11
12
13
14
15
16
17
18
19

20 Infection with replication-impaired lentiviruses can also lead to controlled viremia,
21 as evidenced by the detection of defective HIV-1 variants in long-term nonprogressor
22 patients.^{56–61} To address this possibility, we set out to determine if the virus that infected
23 r08019 harbored any unusual insertions, deletions, or mutations. We first searched for
24 genetic variation in proviral sequences amplified from cryopreserved PBMC collected at
25 wk 2 PI (Fig. 6A). All proviral sequences identified by this analysis contained two amino
26 acid substitutions in Env (C₄₃₂W and I₈₆₃M; data not shown) and one in Nef (Y₃₉C; Fig.
27 6B). Additionally, an 18-bp in-frame deletion in *nef* corresponding to aa ₁₃₉HRILDI₁₄₄
28 was present in 100% of the sequence reads (Fig. 6B & C). Interestingly, a similar 12-bp
29 *nef* deletion affecting aa ₁₄₃DIYL₁₄₆ is found in the SIVmacC8 clone (Fig. 6B), which has
30 been widely used as a live-attenuated SIV vaccine.^{62–66} The highly conserved core
31 region of Nef altered by this deletion is functionally constrained, as evidenced by the
32 instability and functionally impaired activity of the SIVmacC8 Nef protein.⁶⁷ Moreover,
33 SIVmac239 Nef lacking the same four amino acids that are absent from the SIVmacC8
34 Nef protein also exhibits the same dysfunctional phenotype.⁶⁷ Based on the similarity
35 between the SIVmacC8 *nef* deletion and the deletion found in the virus discovered in
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 r08019, we concluded that this animal harbored an attenuated SIV variant as early as
2 wk 2 PI.
3

4
5 Curiously, the six amino acids affected by this deletion are contained within the
6 Mamu-B*08-restricted Nef₁₃₇₋₁₄₆RL10 epitope. In spite of this coincidence, r08019 tested
7 negative for *Mamu-B*08* in two independent MHC typing assays. Moreover, r08019 did
8 not have detectable Nef-specific T-cell responses in an ICS assay performed at wk 3.4
9 PI (Fig. 7), consistent with a mechanism for the emergence of the *nef* deletion that was
10 independent from viral escape driven by T-cell pressure.
11
12
13
14
15
16
17
18
19

20 To rule out the possibility that the *nef* deletion detected in r08019 was an
21 experimental artifact, we sequenced the virus that rebounded following the CD8 α
22 depletion. Strikingly, 100% of circulating viral quasispecies contained the same deletion
23 affecting aa ₁₃₉HRILDI₁₄₄ at wk 38.4 PI, the peak of rebound viremia (Fig. 6A & B).
24 These viruses also exhibited signs of CD8⁺ T-cell-driven sequence evolution, as shown
25 by escape mutations in the Mamu-A*01-restricted Tat₂₈₋₃₅SL8 and Env₇₂₆₋₇₃₅ST10
26 epitopes (data not shown).⁶⁸ However, the Gag₁₈₁₋₁₈₉CM9 epitope was intact at this time
27 point (data not shown). Of note, the Env (C₄₃₂W and I₈₆₃M) and Nef (Y₃₉C) substitutions
28 detected in cell-associated DNA at wk 2 PI were absent from plasma vRNA, indicating
29 possible reversions (data not shown; Fig. 6B). These data confirmed our previous
30 sequencing results and showed that the *nef* deletion was stably maintained in the
31 course of r08019's infection.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Lastly, we investigated the origin of the *nef* deletion detected in r08019. Since
50 this polymorphism was already present at wk 2 PI, we explored whether the challenge
51 inoculum contained *nef*-deleted SIV variants that could have initiated infection in
52 r08019. To do that, we performed whole genome sequencing on our SIVmac239
53 challenge stock, which was produced by propagating the supernatant from transfected
54
55
56
57
58
59
60

1 293T cells on PBMC from SIV naïve rhesus macaques over several days. This analysis
2
3 revealed a relatively homogeneous virus population, with low levels of viral diversity
4
5 detected across the genome (Fig. 8). Importantly, there was no evidence of the *nef*
6
7 deletion in the stock, although the aforementioned Env (C₄₃₂W and I₈₆₃M) and Nef
8
9 (Y₃₉C) amino acid substitutions were present at extremely low frequencies (<0.05%). Of
10
11 note, the threshold frequency for detecting mutant species in this analysis was 0.05%,
12
13 considering that each sequencing reaction contained approximately 2,000 copies of
14
15 viral template. These results implied that either the *nef* deletion arose *in vivo* shortly
16
17 after r08019 became infected or that a rare SIV variant bearing this polymorphism was
18
19 present in the challenge inoculum, went undetected by our sequencing approach, and
20
21 somehow managed to infect r08019.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Here we report the efficacy of a rDNA/rYF17D/rRRV PBB regimen encoding immunodominant SIV epitopes against repeated IR challenges with SIVmac239. Both *Mamu-B*08*⁺ Group 1 vaccinees controlled viral replication to levels rarely seen among MHC class I-matched historical control macaques that have been previously infected with SIVmac239. CD8αβ⁺ T-lymphocytes were likely responsible for this impressive outcome as mAb-mediated depletion of these cells resulted in transient increases in viremia. As for the *Mamu-A*01*⁺ Group 2 vaccinee r08019, virologic control appeared to involve CD8α⁺ lymphocytes and an attenuating deletion in the *nef* gene, although it is also possible that SIV-specific CD8αβ⁺ T-cells participated in viral containment prior to the CD8β depletion. Although the mechanism underlying r08019's impressive containment of SIV infection might not be generalizable, the uniqueness of this animal's course of infection illustrates the complexity of lentivirus-host interactions.

The discovery of a *nef*-deleted SIV variant in r08019 remains a puzzling aspect of this study since this virus was found in all proviral sequences amplified at wk 2 PI but not in the challenge inoculum. Assuming that the low dose SIVmac239 IR challenge regimen employed here resulted in the transmission of a single virus, we can envision at least three possible explanations for the origin of this *nef*-deleted mutant. First, in spite of our inability to detect this deleted form in the SIVmac239 challenge stock, we cannot rigorously rule out the possibility that a minor variant harboring this change is what was transmitted. Indeed, deep sequencing of the inoculum revealed low levels of sequence diversity, probably as a result of propagating the virus on mitogen-activated rhesus macaque PBMC as part of its derivation method.⁶⁹ Given the error-prone nature of retroviral reverse transcription, the low frequency SIV variants detected in the stock

1 likely represent byproducts of multiple rounds of viral replication *in vitro*. Furthermore,
2
3 our inability to detect the *nef*-deleted virus in this stock would be in keeping with the
4
5 technical problems inherent in searching for a rare polymorphism in a highly
6
7 concentrated sample made almost exclusively of WT genomes.
8
9

10
11 Second, it is also possible that a reverse transcription error occurred in the first
12
13 round of viral replication *in vivo*, resulting in the *nef* deletion in question. Indeed, short
14
15 direct repeats are present near the ends of the 18-bp deletion in the SIVmac239 clone
16
17 (Fig. 6C), similar to what has been observed in other examples of appearance of
18
19 deletions in *nef*.⁷⁰ These short direct repeats have been associated with the emergence
20
21 of deletions in retroviral genomes by a mechanism involving template slippage during
22
23 the reverse transcriptase reaction.^{71, 72}
24
25
26
27

28 A third possibility is that the *nef* deletion was selected for *in vivo* within the first
29
30 two weeks after r08019 became infected. Although this 2-wk time frame might appear
31
32 too short for the selection of the *nef*-deleted mutant, there is precedent for
33
34 immunological pressures resulting in an altered variant virus with similar kinetics.^{32, 58, 73}
35
36 While the nature of the selection event(s) implicit in this model remains unknown, it
37
38 probably did not involve T-cell responses since r08019 had no detectable Nef-specific
39
40 T-cells in the acute phase (Fig. 7). Alternatively, the *nef* deletion might have emerged in
41
42 response to selective pressure imposed by NK cells, potentially by a mechanism
43
44 involving killer immunoglobulin-like receptor (KIR) recognition of viral epitopes
45
46 presented by MHC class I molecules.⁷⁴ Along these lines, specific aa substitutions in the
47
48 HIV-1 proteome have been reported to be significantly enriched in infected individuals
49
50 expressing combinations of KIR and MHC class I alleles, indicating that NK cells can
51
52 drive HIV-1 escape.^{75, 76} Given the high epitope density of the core region of Nef,⁷⁷ the
53
54 deleted virus found in r08019 may have been selected for by KIR-expressing NK cells
55
56
57
58
59
60

1 targeting a peptide in that region. Much more extensive analysis will be required to
2 investigate this last possibility.
3
4

5
6 The use of a new anti-CD8 β mAb that selectively eliminates CD8 $\alpha\beta$ ⁺ T-
7 lymphocytes *in vivo* without the caveat of depleting CD8 $\alpha\alpha$ -expressing rhesus macaque
8 NK cells was a key part of this study. A single infusion of this antibody resulted in a
9 surge of SIV replication in the Group 1 macaques but, surprisingly, not in r08019,
10 indicating that this animal did not require an intact CD8 $\alpha\beta$ ⁺ T-cell compartment to
11 maintain control of chronic phase viremia. Importantly, the *nef*-deleted SIV variant that
12 infected r08019 was clearly replication competent, as evidenced by the sharp rise in VL
13 triggered by the subsequent CD8 α depletion. These findings are intriguing and raise the
14 question of what prevented this variant from rebounding in r08019 after the CD8 β
15 depletion. Of note, mAb-directed elimination of lymphocytes in tissues can be less
16 efficient than what is observed in blood. Indeed, macaques subjected to the same
17 CD8 β 255R1 infusion utilized here exhibited incomplete depletion of CD8⁺ T-cells in
18 lymph node and duodenal biopsies in the first few weeks after the CD8 β 255R1 infusion
19 ([http://www.nhpreagents.org/NHP/Download.aspx?View=1&FileGUID=b7154cba-be30-
20 431c-834a-444c9376](http://www.nhpreagents.org/NHP/Download.aspx?View=1&FileGUID=b7154cba-be30-431c-834a-444c9376)). In this regard, we cannot discard the possibility that residual
21 SIV-specific CD8 $\alpha\beta$ ⁺ T-cells present in relevant sites of SIV persistence prevented virus
22 rebound in r08019 following the CD8 β 255R1 infusion. Alternatively, NK cells could also
23 have suppressed viral replication during the period of CD8 $\alpha\beta$ ⁺ T-cell deficiency. Along
24 these lines, a vigorous expansion of NK cells coincided with the re-establishment of
25 virologic control in the Group 1 macaques. Although epidemiological and *in vitro* data
26 support a role for NK cells in lentivirus control,⁷⁸ previous attempts to deplete these
27 lymphocytes *in vivo* by the infusion of an anti-CD16 mAb revealed no significant
28 contribution to the containment of SIV infection.^{79, 80} Critically, however, the majority of
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 rhesus macaque NK cells in the gut and vaginal mucosae do not express CD16,⁸¹
2
3 indicating that *in vivo* depletion of CD16⁺ cells might not address the antiviral potential
4
5 of tissue-resident NK cells. Considering this heterogeneity, it is difficult to assess the
6
7 extent to which NK cells controlled viral replication in r08019 since our phenotypic
8
9 analysis focused on CD3⁻CD8αα⁺CD16⁺ cells—the dominant NK cell subset in macaque
10
11 peripheral blood.⁵² Thus, while our data provide circumstantial evidence for NK cell-
12
13 mediated control of SIV replication in one animal, they also illustrate the challenges of
14
15 studying NK cells in nonhuman primates without more inclusive and selective strategies
16
17 for depleting these lymphocytes *in vivo*.
18
19
20
21
22

23 Given the increase in CD8αα⁺ T-cell counts after the CD8β depletion, especially
24
25 in the Group 1 macaque r07032, we also considered the possibility that these cells
26
27 contributed to control of SIV replication during this period. The physiological role of
28
29 CD8αα homodimers expressed by T-cells is not completely understood. Previous
30
31 studies in mice have shown that while both CD8αα and CD8αβ isoforms can bind to
32
33 MHC class I molecules,^{82–84} CD8αβ heterodimers appear to be required for the
34
35 selection of MHC class I-restricted CD8⁺ T-lymphocytes in the thymus.⁵⁰ Furthermore,
36
37 the CD8αα molecule has been described as a marker for T-cell activation and is
38
39 primarily expressed by mucosal T-cells.^{51, 85, 86} Interestingly, human CD8αα⁺ T-cells
40
41 residing in genital skin have been recently implicated in the containment of herpes
42
43 simplex virus-2 reactivation,⁸⁷ indicating that these cells participate in defense against
44
45 persistent viral infections. Although CD8αα⁺ T-cells might be part of a unique, regionally
46
47 specialized, lineage of T-lymphocytes, it is not clear if the peripheral CD8αα⁺ T-cells
48
49 identified here are examples of such cells. Alternatively, they could have comprised pre-
50
51 existing CD8αα⁺CD8αβ⁺ T-cells in PBMC that internalized their surface CD8αβ
52
53 heterodimers upon ligation of the anti-CD8β mAb. A detailed analysis of the T-cell
54
55
56
57
58
59
60

1
2 receptor clonotypes, Ag specificities, and tissue distribution of CD8 α ⁺ and CD8 α β ⁺ T-
3
4 cells before and after depletion of CD8 α β ⁺ lymphocytes would have been needed to
5
6 address this possibility. Nevertheless, in light of the recent identification of tissue-
7
8 resident human CD8 α ⁺ T-cells endowed with potent antiviral activity,⁸⁷ characterizing
9
10 the role of these unconventional T-lymphocytes during lentivirus infections may lead to
11
12 new strategies for eliciting cellular immunity against HIV.
13
14

15
16 In conclusion, here we show that SIV-specific CD8⁺ T-cells elicited by a
17
18 rDNA/rYF17D/rRRV PBB regimen afforded significant control of SIVmac239 replication
19
20 in 3/4 vaccinees. Since vaccine-induced CD8⁺ T-cells in these animals were focused on
21
22 a single immunodominant SIV epitope, we are currently exploring if expanding the CD8⁺
23
24 T-cell response against other viral Ags can improve vaccine efficacy. We also explored
25
26 the basis for the unusual control of SIVmac239 replication manifested by one
27
28 vaccinated macaque and showed that, surprisingly, this animal harbored a *nef*-deleted
29
30 mutant as early as 2 wks PI. Subsequent CD8 depletions suggested that replication of
31
32 this SIV variant may have been contained by CD8 α -expressing lymphocytes,
33
34 warranting further investigation of the antiviral capacity of NK cells *in vivo*. While we
35
36 could not pinpoint the origin of the *nef*-deleted virus, three possible explanations
37
38 involving both stochastic and selective events were presented based on the available
39
40 data. Collectively, these data provide additional insights into the full spectrum of
41
42 virologic control of lentivirus infection.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENTS

We are grateful to Brandon Keele for helpful comments on this manuscript and to Dr. Elizabeth Connick for quantifying SIV-producing cells in lymph node biopsies by *in situ* hybridization. We also thank Rebecca Shoemaker, Nicholas Pomplun, Jessica Furlott, Randy Fast, Kelli Oswald, Marlon Veloso de Santana, and William Lauer for technical support. We also wish to acknowledge Eric Peterson, Kristin Crosno, and Kevin Brunner for providing excellent care of the rhesus macaques used in this experiment; Teresa Maidana Giret for confirming the MHC class I genotype of the monkeys in this study; Leydi Guzman for administrative assistance; and Christopher Parks for facilitating the electroporated rDNA vaccinations employed here.

This work was funded by Public Health Service grant R37AI052056 to D.I.W. and was supported in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E and from the National Institute of Allergy and Infectious Diseases through P01 AI074415 (T.M.A.). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The mAbs used in the *in vivo* lymphocyte depletions were produced by the NIH Nonhuman Primate Reagent Resource (OD010976 and HHSN2722001300031C, K.A.R.).

DISCLAIMER

TA's spouse was an employee of Bristol Myers Squibb, which has a focus in Virology, specifically treatments for hepatitis B and C and HIV/AIDS. TA's spouse no longer works for BMS and only retained a small stock interest in the public company.

1 TA's interests were reviewed and managed by Massachusetts General Hospital and
2
3
4 Partners HealthCare in accordance with their conflict of interest policies.
5
6
7

8 **SEQUENCE DATA**

9
10
11
12 All reads have been deposited to the NCBI Sequence Read Archive under
13
14 accession number SRP016012.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Allen TM, Altfeld M, Geer SC et al.: Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. *J Virol* 2005;79:13239-13249.
2. Friedrich TC, Valentine LE, Yant LJ et al.: Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. *J Virol* 2007;81:3465-3476.
3. Kiepiela P, Ngumbela K, Thobakgale C et al.: CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. *Nat Med* 2007;13:46-53.
4. Koup RA, Safrit JT, Cao Y et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol* 1994;68:4650-4655.
5. Schmitz JE, Kuroda MJ, Santra S et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. *Science* 1999;283:857-860.
6. Buchbinder SP, Mehrotra DV, Duerr A et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. *Lancet* 2008;372:1881-1893.
7. Gray GE, Allen M, Moodie Z et al.: Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind,

- 1
2 randomised, placebo-controlled test-of-concept phase 2b study. *Lancet Infect Dis*
3
4 2011;11:507-515.
5
6
7
8 8. Hammer SM, Sobieszczyk ME, Janes H et al.: Efficacy trial of a DNA/rAd5 HIV-1
9 preventive vaccine. *N Engl J Med* 2013;369:2083-2092.
10
11
12
13 9. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects
14 of a live attenuated SIV vaccine with a deletion in the nef gene. *Science*
15 1992;258:1938-1941.
16
17
18
19
20
21 10. Fukazawa Y, Park H, Cameron MJ et al.: Lymph node T cell responses predict the
22 efficacy of live attenuated SIV vaccines. *Nat Med* 2012;18:1673-1681.
23
24
25
26
27 11. Barouch DH: Novel adenovirus vector-based vaccines for HIV-1. *Curr Opin HIV*
28 *AIDS* 2010;5:386-390.
29
30
31
32
33 12. Excler JL, Parks CL, Ackland J, Rees H, Gust ID, Koff WC: Replicating viral
34 vectors as HIV vaccines: summary report from the IAVI-sponsored satellite
35 symposium at the AIDS vaccine 2009 conference. *Biologicals* 2010;38:511-521.
36
37
38
39
40
41 13. Pantaleo G, Esteban M, Jacobs B, Tartaglia J: Poxvirus vector-based HIV
42 vaccines. *Curr Opin HIV AIDS* 2010;5:391-396.
43
44
45
46
47 14. Sardesai NY, Weiner DB: Electroporation delivery of DNA vaccines: prospects for
48 success. *Curr Opin Immunol* 2011;23:421-429.
49
50
51
52
53 15. Casimiro DR, Wang F, Schleif WA et al.: Attenuation of simian immunodeficiency
54 virus SIVmac239 infection by prophylactic immunization with dna and recombinant
55 adenoviral vaccine vectors expressing Gag. *J Virol* 2005;79:15547-15555.
56
57
58
59
60

- 1
2 16. Hel Z, Nacsa J, Trynieszewska E et al.: Containment of simian immunodeficiency
3
4 virus infection in vaccinated macaques: correlation with the magnitude of virus-
5
6 specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol
7
8 2002;169:4778-4787.
9
- 10
11
12 17. Hel Z, Tsai WP, Trynieszewska E et al.: Improved vaccine protection from simian
13
14 AIDS by the addition of nonstructural simian immunodeficiency virus genes. J
15
16 Immunol 2006;176:85-96.
17
18
- 19
20 18. Lasaro MO, Haut LH, Zhou X et al.: Vaccine-induced T cells provide partial
21
22 protection against high-dose rectal SIVmac239 challenge of rhesus macaques. Mol
23
24 Ther 2011;19:417-426.
25
26
- 27
28 19. Liu J, O'Brien KL, Lynch DM et al.: Immune control of an SIV challenge by a T-cell-
29
30 based vaccine in rhesus monkeys. Nature 2009;457:87-91.
31
32
- 33
34 20. Pellett PE, Roizman B: Herpesviridae. In: *Fields Virology*. (Knipe DM, Howley PM,
35
36 ed.) Lippincott Williams & Wilkins, Philadelphia, PA, 2013, pp. 1802-1819.
37
38
- 39
40 21. Torti N, Oxenius A: T cell memory in the context of persistent herpes viral
41
42 infections. Viruses 2012;4:1116-1143.
43
44
- 45
46 22. Masopust D, Schenkel JM: The integration of T cell migration, differentiation and
47
48 function. Nat Rev Immunol 2013;13:309-320.
49
50
- 51
52 23. Hansen SG, Vieville C, Whizin N et al.: Effector memory T cell responses are
53
54 associated with protection of rhesus monkeys from mucosal simian
55
56 immunodeficiency virus challenge. Nat Med 2009;15:293-299.
57
58
59
60

- 1
2 24. Hansen SG, Ford JC, Lewis MS et al.: Profound early control of highly pathogenic
3
4 SIV by an effector memory T-cell vaccine. *Nature* 2011;473:523-527.
5
6
- 7
8 25. Hansen SG, Piatak MJ, Ventura AB et al.: Immune clearance of highly pathogenic
9
10 SIV infection. *Nature* 2013;502:100-104.
11
12
- 13
14 26. Bilello JP, Morgan JS, Damania B, Lang SM, Desrosiers RC: A genetic system for
15
16 rhesus monkey rhadinovirus: use of recombinant virus to quantitate antibody-
17
18 mediated neutralization. *J Virol* 2006;80:1549-1562.
19
20
- 21
22 27. Bilello JP, Manrique JM, Shin YC et al.: Vaccine protection against simian
23
24 immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus. *J*
25
26 *Virol* 2011;85:12708-12720.
27
28
- 29
30 28. Hansen SG, Sacha JB, Hughes CM et al.: Cytomegalovirus vectors violate CD8+ T
31
32 cell epitope recognition paradigms. *Science* 2013;340:1237874.
33
34
- 35
36 29. Hansen SG, Wu HL, Burwitz BJ et al.: Broadly targeted CD8(+) T cell responses
37
38 restricted by major histocompatibility complex E. *Science* 2016;351:714-720.
39
40
- 41
42 30. Masopust D, Ha SJ, Vezys V, Ahmed R: Stimulation history dictates memory CD8
43
44 T cell phenotype: implications for prime-boost vaccination. *J Immunol*
45
46 2006;177:831-839.
47
48
- 49
50 31. Thompson EA, Beura LK, Nelson CE, Anderson KG, Vezys V: Shortened Intervals
51
52 during Heterologous Boosting Preserve Memory CD8 T Cell Function but
53
54 Compromise Longevity. *J Immunol* 2016;196:3054-3063.
55
56
- 57
58 32. Martins MA, Tully DC, Cruz MA et al.: Vaccine-Induced Simian Immunodeficiency
59
60

- 1
2 Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for
3
4 Escape Variants Shortly after Infection. J Virol 2015;89:10802-10820.
5
6
7
8 33. Martins MA, Wilson NA, Piaskowski SM et al.: Vaccination with Gag, Vif, and Nef
9 gene fragments affords partial control of viral replication after mucosal challenge
10 with SIVmac239. J Virol 2014;88:7493-7516.
11
12
13
14
15
16 34. Schmitz JE, Simon MA, Kuroda MJ et al.: A nonhuman primate model for the
17 selective elimination of CD8+ lymphocytes using a mouse-human chimeric
18 monoclonal antibody. Am J Pathol 1999;154:1923-1932.
19
20
21
22
23
24 35. Gonzalez-Nieto L, Domingues A, Ricciardi M et al.: Analysis of Simian
25 Immunodeficiency Virus-specific CD8+ T-cells in Rhesus Macaques by Peptide-
26 MHC-I Tetramer Staining. J Vis Exp 2016
27
28
29
30
31
32 36. Schmitz JE, Forman MA, Lifton MA et al.: Expression of the CD8alpha beta-
33 heterodimer on CD8(+) T lymphocytes in peripheral blood lymphocytes of human
34 immunodeficiency virus- and human immunodeficiency virus+ individuals. Blood
35 1998;92:198-206.
36
37
38
39
40
41
42 37. Parham P: Antigen Recognition by T Lymphocytes. In: *The Immune System*.
43 (Foltin J, Masson S, Ghezzi K, Engels A, Lawrence E, Jeffcock E, ed.) Garland
44 Science, Taylor & Francis Group, LLC, New York, NY, 2009, pp. 125-154.
45
46
47
48
49
50 38. Cline AN, Bess JW, Piatak MJ, Lifson JD: Highly sensitive SIV plasma viral load
51 assay: practical considerations, realistic performance expectations, and application
52 to reverse engineering of vaccines for AIDS. J Med Primatol 2005;34:303-312.
53
54
55
56
57
58 39. Mudd PA, Martins MA, Ericson AJ et al.: Vaccine-induced CD8+ T cells control
59
60

- 1
2 AIDS virus replication. *Nature* 2012;491:129-133.
3
4
- 5 40. Bimber BN, Dudley DM, Lauck M et al.: Whole-genome characterization of human
6 and simian immunodeficiency virus intrahost diversity by ultradeep
7 pyrosequencing. *J Virol* 2010;84:12087-12092.
8
9
- 10 41. Yang X, Charlebois P, Gnerre S et al.: De novo assembly of highly diverse viral
11 populations. *BMC Genomics* 2012;13:475.
12
13
- 14 42. Henn MR, Boutwell CL, Charlebois P et al.: Whole genome deep sequencing of
15 HIV-1 reveals the impact of early minor variants upon immune recognition during
16 acute infection. *PLoS Pathog* 2012;8:e1002529.
17
18
- 19 43. Yang X, Charlebois P, Macalalad A, Henn MR, Zody MC: V-Phaser 2: variant
20 inference for viral populations. *BMC Genomics* 2013;14:674.
21
22
- 23 44. Allen TM, Sidney J, del Guercio MF et al.: Characterization of the peptide binding
24 motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an
25 immunodominant CTL epitope from simian immunodeficiency virus. *J Immunol*
26 1998;160:6062-6071.
27
28
- 29 45. Loffredo JT, Friedrich TC, Leon EJ et al.: CD8+ T cells from SIV elite controller
30 macaques recognize Mamu-B*08-bound epitopes and select for widespread viral
31 variation. *PLoS ONE* 2007;2:e1152.
32
33
- 34 46. Loffredo JT, Maxwell J, Qi Y et al.: Mamu-B*08-positive macaques control simian
35 immunodeficiency virus replication. *J Virol* 2007;81:8827-8832.
36
37
- 38 47. Masopust D, Picker LJ: Hidden memories: frontline memory T cells and early
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 pathogen interception. *J Immunol* 2012;188:5811-5817.
- 2
- 3
- 4
- 5 48. Damania B, Desrosiers RC: Simian homologues of human herpesvirus 8. *Philos*
- 6
- 7 *Trans R Soc Lond B Biol Sci* 2001;356:535-543.
- 8
- 9
- 10
- 11 49. Desrosiers RC, Sasseville VG, Czajak SC et al.: A herpesvirus of rhesus monkeys
- 12
- 13 related to the human Kaposi's sarcoma-associated herpesvirus. *J Virol*
- 14
- 15 1997;71:9764-9769.
- 16
- 17
- 18
- 19 50. Bosselut R, Kubo S, Guinter T et al.: Role of CD8beta domains in CD8 coreceptor
- 20
- 21 function: importance for MHC I binding, signaling, and positive selection of CD8+ T
- 22
- 23 cells in the thymus. *Immunity* 2000;12:409-418.
- 24
- 25
- 26
- 27 51. Cheroutre H: Starting at the beginning: new perspectives on the biology of mucosal
- 28
- 29 T cells. *Annu Rev Immunol* 2004;22:217-246.
- 30
- 31
- 32
- 33 52. Webster RL, Johnson RP: Delineation of multiple subpopulations of natural killer
- 34
- 35 cells in rhesus macaques. *Immunology* 2005;115:206-214.
- 36
- 37
- 38
- 39 53. Jin X, Bauer DE, Tuttleton SE et al.: Dramatic rise in plasma viremia after CD8(+)
- 40
- 41 T cell depletion in simian immunodeficiency virus-infected macaques. *J Exp Med*
- 42
- 43 1999;189:991-998.
- 44
- 45
- 46
- 47 54. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA: Administration
- 48
- 49 of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric
- 50
- 51 simian/human immunodeficiency virus during primary infections of rhesus
- 52
- 53 macaques. *J Virol* 1998;72:164-169.
- 54
- 55
- 56
- 57 55. Okoye A, Park H, Rohankhedkar M et al.: Profound CD4+/CCR5+ T cell expansion
- 58
- 59
- 60

1 is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV
2 pathogenesis. J Exp Med 2009;206:1575-1588.
3
4

- 5
6
7
8 56. Alexander L, Aquino-DeJesus MJ, Chan M, Andiman WA: Inhibition of human
9 immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in
10 HIV-1 Vif from a nonprogressing mother and child. J Virol 2002;76:10533-10539.
11
12
13
14
15
16 57. Deacon NJ, Tsykin A, Solomon A et al.: Genomic structure of an attenuated quasi
17 species of HIV-1 from a blood transfusion donor and recipients. Science
18 1995;270:988-991.
19
20
21
22
23
24 58. Kestler HW, Ringler DJ, Mori K et al.: Importance of the nef gene for maintenance
25 of high virus loads and for development of AIDS. Cell 1991;65:651-662.
26
27
28
29
30 59. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC: Brief report:
31 absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1
32 infection. N Engl J Med 1995;332:228-232.
33
34
35
36
37
38 60. Mariani R, Kirchhoff F, Greenough TC, Sullivan JL, Desrosiers RC, Skowronski J:
39 High frequency of defective nef alleles in a long-term survivor with nonprogressive
40 human immunodeficiency virus type 1 infection. J Virol 1996;70:7752-7764.
41
42
43
44
45
46 61. Alexander L, Weiskopf E, Greenough TC et al.: Unusual polymorphisms in human
47 immunodeficiency virus type 1 associated with nonprogressive infection. J Virol
48 2000;74:4361-4376.
49
50
51
52
53
54 62. Rud EW, Yon JR, Larder BA, Clarke BE, Cook N, Cranage MP: Infectious
55 molecular clones of SIVmac32H: Nef deletion controls ability to reisolate virus from
56 rhesus macaques. In: *Vaccines 92: Modern Approaches to New Vaccines*
57
58
59
60

- 1
2 *Including Prevention of AIDS.* (Brown F, Chanock RM, Ginsberg HS, Norrby E,
3 ed.) Cold Spring Harbor Laboratory, New York, 1992, pp. 229-235.
4
5
6
7
8 63. Rud EW, Cranage M, Yon J et al.: Molecular and biological characterization of
9 simian immunodeficiency virus macaque strain 32H proviral clones containing nef
10 size variants. *J Gen Virol* 1994;75:529-543.
11
12
13
14
15
16 64. Cranage MP, Whatmore AM, Sharpe SA et al.: Macaques infected with live
17 attenuated SIVmac are protected against superinfection via the rectal mucosa.
18 *Virology* 1997;229:143-154.
19
20
21
22
23
24 65. Cranage MP, Sharpe SA, Whatmore AM et al.: In vivo resistance to simian
25 immunodeficiency virus superinfection depends on attenuated virus dose. *J Gen*
26 *Virol* 1998;79:1935-1944.
27
28
29
30
31
32 66. Sharpe SA, Whatmore AM, Hall GA, Cranage MP: Macaques infected with
33 attenuated simian immunodeficiency virus resist superinfection with virulence-
34 revertant virus. *J Gen Virol* 1997;78:1923-1927.
35
36
37
38
39
40 67. Carl S, Iafrate AJ, Skowronski J, Stahl-Hennig C, Kirchhoff F: Effect of the
41 attenuating deletion and of sequence alterations evolving in vivo on simian
42 immunodeficiency virus C8-Nef function. *J Virol* 1999;73:2790-2797.
43
44
45
46
47
48 68. Loffredo JT, Valentine LE, Watkins DI: Beyond Mamu-A*01+ Indian Rhesus
49 Macaques: Continued Discovery of New MHC Class I Molecules that Bind
50 Epitopes from the Simian AIDS Viruses. *HIV molecular immunology* 2006;2007:29-
51 51.
52
53
54
55
56
57
58
59 69. Del Prete GQ, Scarlotta M, Newman L et al.: Comparative characterization of
60

- 1
2 transfection- and infection-derived simian immunodeficiency virus challenge stocks
3
4 for in vivo nonhuman primate studies. *J Virol* 2013;87:4584-4595.
5
6
7
8 70. Kirchhoff F, Kestler HW, Desrosiers RC: Upstream U3 sequences in simian
9 immunodeficiency virus are selectively deleted in vivo in the absence of an intact
10 nef gene. *J Virol* 1994;68:2031-2037.
11
12
13
14
15
16 71. Pathak VK, Temin HM: Broad spectrum of in vivo forward mutations,
17 hypermutations, and mutational hotspots in a retroviral shuttle vector after a single
18 replication cycle: deletions and deletions with insertions. *Proc Natl Acad Sci U S A*
19 1990;87:6024-6028.
20
21
22
23
24
25
26 72. Pulsinelli GA, Temin HM: Characterization of large deletions occurring during a
27 single round of retrovirus vector replication: novel deletion mechanism involving
28 errors in strand transfer. *J Virol* 1991;65:4786-4797.
29
30
31
32
33
34 73. Klein F, Nogueira L, Nishimura Y et al.: Enhanced HIV-1 immunotherapy by
35 commonly arising antibodies that target virus escape variants. *J Exp Med*
36 2014;211:2361-2372.
37
38
39
40
41
42 74. Jost S, Altfeld M: Evasion from NK cell-mediated immune responses by HIV-1.
43 *Microbes Infect* 2012;14:904-915.
44
45
46
47
48 75. Alter G, Heckerman D, Schneidewind A et al.: HIV-1 adaptation to NK-cell-
49 mediated immune pressure. *Nature* 2011;476:96-100.
50
51
52
53
54 76. Holzemer A, Thobakgale CF, Jimenez Cruz CA et al.: Selection of an HLA-
55 C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral
56 Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in
57
58
59
60

- 1 South Africa. PLoS Med 2015;12:e1001900; discussion e1001900.
- 2
- 3
- 4
- 5 77. Carlson JM, Brumme CJ, Martin E et al.: Correlates of protective cellular immunity
- 6 revealed by analysis of population-level immune escape pathways in HIV-1. J Virol
- 7 2012;86:13202-13216.
- 8
- 9
- 10
- 11
- 12
- 13 78. Scully E, Alter G: NK Cells in HIV Disease. Curr HIV/AIDS Rep 2016
- 14
- 15
- 16
- 17 79. Choi EI, Reimann KA, Letvin NL: In vivo natural killer cell depletion during primary
- 18 simian immunodeficiency virus infection in rhesus monkeys. J Virol 2008;82:6758-
- 19 6761.
- 20
- 21
- 22
- 23
- 24
- 25 80. Choi EI, Wang R, Peterson L, Letvin NL, Reimann KA: Use of an anti-CD16
- 26 antibody for in vivo depletion of natural killer cells in rhesus macaques.
- 27 Immunology 2008;124:215-222.
- 28
- 29
- 30
- 31
- 32
- 33 81. Reeves RK, Gillis J, Wong FE, Yu Y, Conole M, Johnson RP: CD16- natural killer
- 34 cells: enrichment in mucosal and secondary lymphoid tissues and altered function
- 35 during chronic SIV infection. Blood 2010;115:4439-4446.
- 36
- 37
- 38
- 39
- 40
- 41 82. Garcia KC, Scott CA, Brunmark A et al.: CD8 enhances formation of stable T-cell
- 42 receptor/MHC class I molecule complexes. Nature 1996;384:577-581.
- 43
- 44
- 45
- 46
- 47 83. Kern P, Hussey RE, Spoerl R, Reinherz EL, Chang HC: Expression, purification,
- 48 and functional analysis of murine ectodomain fragments of CD8alphaalpha and
- 49 CD8alphabeta dimers. J Biol Chem 1999;274:27237-27243.
- 50
- 51
- 52
- 53
- 54
- 55 84. Wyer JR, Willcox BE, Gao GF et al.: T cell receptor and coreceptor CD8
- 56 alphaalpha bind peptide-MHC independently and with distinct kinetics. Immunity
- 57
- 58
- 59
- 60

1
2 1999;10:219-225.
3
4

- 5 85. Cheroutre H, Lambolez F, Mucida D: The light and dark sides of intestinal
6
7 intraepithelial lymphocytes. Nat Rev Immunol 2011;11:445-456.
8
9
10
11 86. Madakamutil LT, Christen U, Lena CJ et al.: CD8alpha-mediated survival and
12
13 differentiation of CD8 memory T cell precursors. Science 2004;304:590-593.
14
15
16
17 87. Zhu J, Peng T, Johnston C et al.: Immune surveillance by CD8alpha+ skin-
18
19 resident T cells in human herpes virus infection. Nature 2013;497:494-497.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INDIVIDUAL TO WHOM REPRINT REQUESTS SHOULD BE DIRECTED

David I. Watkins, dwatkins@med.miami.edu.

Address: Life Science Tech Park/Pathology, 1951 NW 7th Ave, room 2340, Miami, FL

33136. Phone: 305 243-0405; Fax: 305 243-7667.

FIGURE LEGENDS

Figure 1. Design, immunogenicity, and efficacy of a rDNA/rYF17D/rRRV regimen encoding immunodominant classical CD8⁺ T-cell epitopes. A) Two *Mamu-B*08*⁺ (Group 1) and two *Mamu-A*01*⁺ (Group 2) Indian rhesus macaques were immunized with a heterologous prime/boost/boost vaccine regimen aimed at eliciting high frequency CD8⁺ T_{EM} responses against immunodominant SIV determinants. These animals were primed once with rDNA delivered by intramuscular electroporation followed by two viral vector boosts with rYF17D and then rRRV. Both the rDNA plasmids and the rYF17D encoded SIVmac239 minigenes corresponding to aa 45-210 of the Nef protein (Group 1) or aa 178-258 of the Gag polyprotein (Group 2). The rRRV vectors expressed a *rev-tat-nef* fusion (Group 1) or full-length *gag* (Group 2). Of note, all macaques in Groups 1 and 2 were seropositive for RRV at the time of the rRRV vaccinations. In keeping with the animals' expressed MHC class I genotypes, macaques in Group 1 received inserts encoding the Mamu-B*08-restricted Nef₁₃₇₋₁₄₆RL10 epitope while those in Group 2 were vaccinated with *gag* sequences containing the Mamu-A*01-restricted Gag₁₈₁₋₁₈₉CM9 determinant. Nineteen weeks following the rRRV boost, we began challenging the Group 1 and Group 2 monkeys every week with intrarectal (IR) inoculations of 200 TCID₅₀ of an *in vivo*-titered SIVmac239 stock.³² B & C) Vaccine-induced SIV-specific CD8⁺ T-cell responses in Group 1 (B) and Group 2 (C). We monitored the ontogeny of vaccine-elicited CD8⁺ T-cell responses in Groups 1 and 2 by staining PBMC with fluorochrome-labeled

1
2
3 Mamu-B*08/Nef₁₃₇₋₁₄₆RL10 and Mamu-A*01/Gag₁₈₁₋₁₈₉CM9 tetramers,
4
5 respectively. Only time points following the rYF17D boost are displayed. The last
6
7 measurement was performed at wk 34 post rYF17D vaccination, 3 wks prior to
8
9 the 1st IR challenge with SIVmac239. D & E) Memory phenotype of vaccine-
10
11 induced CD8⁺ T-cells in Group 1 (D) and Group 2 (E) at wk 34 post rYF17D
12
13 vaccination. Based on the expression of CD28 and CCR7, tetramer⁺CD8⁺ T-cells
14
15 in PBMC were classified as fully-differentiated effector memory (T_{EM2}; CD28⁻
16
17 CCR7⁻), transitional memory (T_{EM1}; CD28⁺CCR7⁻), or central memory (T_{CM};
18
19 CD28⁺CCR7⁺) subsets. F) Rate at which macaques in Groups 1 and 2 became
20
21 infected following repeated IR challenges with SIVmac239. The frequency of
22
23 each animal's tetramer⁺CD8⁺ T-cells at wk 34 post rYF17D is shown as a
24
25 reference. G) Log-transformed viral loads (VLs) after SIVmac239 infection. The
26
27 dashed line in the graph is for reference only and indicates a VL of 10⁶ vRNA
28
29 copies/mL. The dotted line is also for reference only and denotes a VL of 10³
30
31 vRNA copies/mL. The limit of reliable quantitation of this VL assay was 15 vRNA
32
33 copies/mL of plasma. To assess the extent to which vaccinees in Groups 1 and 2
34
35 decreased plasma viremia, geometric means of VLs measured in unvaccinated
36
37 MHC class I-matched macaques that were rectally infected with SIVmac239 as
38
39 part of current and recent studies conducted in our laboratory are also plotted
40
41 (Martins *et al.*, unpublished observations).^{32, 33, 39} These geometric means were
42
43 calculated based on VLs measured within wks 1-20 PI in twelve *Mamu-B*08*⁺
44
45 and eight *Mamu-A*01*⁺ macaques.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 2. Peak and setpoint viral loads in Groups 1 and 2 compared to**
4 **historical SIVmac239-infected macaques.** A) Log-transformed peak and
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Peak and setpoint viral loads in Groups 1 and 2 compared to historical SIVmac239-infected macaques. A) Log-transformed peak and setpoint VLs in r04132 and r07032 were plotted alongside the same VL values from *Mamu-B*08*⁺ rhesus macaques that were rectally infected with SIVmac239 as part of ongoing and recent studies conducted in our laboratory (Martins *et al.*, unpublished observations).^{32, 33, 39} Each symbol corresponds to one monkey. For this analysis, unvaccinated macaques ($n = 12$) are denoted by open circles whereas vaccinated monkeys ($n = 16$) are denoted by open triangles. B) Peak and setpoint VLs in r08019 and r01049 are displayed alongside VLs from SIVmac239-infected, *Mamu-A*01*⁺ rhesus macaques. As in A, open circles correspond to unvaccinated monkeys ($n = 8$) whereas open triangles indicate vaccinated animals ($n = 8$). In all cases, setpoint was determined as the geometric mean of VLs measured between wk 6 PI and the last available post-infection time point. Bars correspond to medians.

39 **Figure 3. Outcome of sequential *in vivo* lymphocyte depletions.** A) Both
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3. Outcome of sequential *in vivo* lymphocyte depletions. A) Both Group 1 vaccinees (r04132 and r07032) and r08019 received a single infusion of 50 mg/kg of a new CD8 β -specific mAb (CD8 β 255R1) designed to deplete CD8 β -expressing cells *in vivo*. At the time of the CD8 β depletion, r04132 was at wk 31 PI; r07032 was at wk 34 PI; and r08019 was at wk 27 PI. Ten weeks after the CD8 β depletion, CD8 α ⁺ lymphocytes in r04132 and r08019 were depleted by a single infusion of 50 mg/kg of the anti-CD8 α mAb MT807R1. Due to adverse events experienced during the CD8 β depletion, r07032 was not subjected to this

1
2
3 treatment. B-E) Absolute lymphocyte counts in blood following the CD8 β and
4 CD8 α depletions. B) CD8 $\alpha\beta^+$ T-cells (live CD3 $^+$ CD8 $\alpha\alpha^-$ CD8 $\alpha\beta^+$ lymphocytes). C)
5
6 NK cells (live CD3 $^-$ CD8 $\alpha\alpha^+$ CD16 $^+$ lymphocytes). D) CD8 $\alpha\alpha^+$ T-cells (live
7
8 CD3 $^+$ CD8 $\alpha\alpha^+$ CD8 $\alpha\beta^-$ lymphocytes). E) CD4 $^+$ T-cells (considered as live
9
10 CD3 $^+$ CD8 $\alpha\alpha^-$ CD8 $\alpha\beta^-$ lymphocytes). F) Log-transformed VLs after the CD8 β and
11
12 CD8 α depletions. The time points when r08019 experienced VLs at or above the
13
14 limit of reliable quantitation (15 vRNA copies/mL) are crossed in red. VLs in this
15
16 animal were <15 vRNA copies/mL at all other time points shown in panel F.
17
18
19
20
21
22
23

24 **Figure 4. Outcome of CD8 β depletion in two additional SIV-infected**
25 **macaques manifesting control of chronic phase viremia.** A) The *Mamu-*
26 *B*08+* rhesus macaques r09089 and r09037 were rectally infected with
27 SIVmac239 as part of a recent experiment conducted by our laboratory and
28 controlled chronic phase viremia³². Similar to the procedure described in Fig. 3,
29 these animals received a single infusion of 50 mg/kg of the CD8 β 255R1 mAb. At
30 the time of the CD8 β depletion, r09089 was at wk 103 PI and r09037 was at wk
31 109 PI. B-E) Absolute lymphocyte counts in blood following the CD8 β and CD8 α
32 depletions. B) CD8 $\alpha\beta^+$ T-cells (live CD3 $^+$ CD8 $\alpha\alpha^-$ CD8 $\alpha\beta^+$ lymphocytes). C) NK
33 cells (live CD3 $^-$ CD8 $\alpha\alpha^+$ CD16 $^+$ lymphocytes). D) CD8 $\alpha\alpha^+$ T-cells (live
34 CD3 $^+$ CD8 $\alpha\alpha^+$ CD8 $\alpha\beta^-$ lymphocytes). E) CD4 $^+$ T-cells (considered as live
35 CD3 $^+$ CD8 $\alpha\alpha^-$ CD8 $\alpha\beta^-$ lymphocytes). F) Log-transformed VLs after the CD8 β
36
37 depletion.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 5. Endpoint titers of anti-Ig antibodies in r04132 and r08019.** Pre- and
4 post-CD8 β depletion plasma from r04132 (A) and r08019 (B) were tested for
5 reactivity to the CD8 β 255R1 (left panels) and MT807R1 (right panels) mAbs. The
6 goal of this assay was to determine the endpoint titer of antibodies against each
7 mAb, that is, the highest plasma dilution where the absorbance level of the post-
8 depletion sample was >2-fold higher than the corresponding pre-depletion
9 sample. Plasma saved 8 days before and 22 days after the CD8 β 255R1 infusion
10 served as the pre- and post-depletion samples, respectively. The endpoint titers
11 of anti-CD8 β 255R1 antibodies are underlined and in boldface type below each
12 graph. Anti-MT807R1 antibodies could not be detected in either r04132 or
13 r08019 by this methodology.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 **Figure 6. Viral sequencing analysis in r08019.** A) Scheme of the viral
33 sequencing analysis performed in r08019. We searched for genetic variation in
34 SIV DNA obtained from cryopreserved PBMC collected at wk 2 PI. Viral
35 sequences from nucleotides 7,565-9,979 were amplified, which encode aa 324-
36 879 of Env and the entire Nef protein (aa 1-263). Eleven days after the infusion
37 of the anti-CD8 α mAb, when r08019 experienced a VL of 190,000 vRNA
38 copies/mL (wk 38.4 PI), we isolated vRNA from plasma and sequenced the SIV
39 genomes circulating at this time point. B) Alignment of predicted Nef amino acid
40 sequences found in r08019. Conceptual translations of the *nef* sequences
41 obtained from PBMC-associated SIV DNA at wk 2 PI and from plasma vRNA at
42 wk 38.4 PI are shown in the upper rows. As a reference, the aa sequence of the
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 SIVmac239 Nef protein is shown in the bottom row. The location of the six-amino
4 acid Nef deletion (₁₃₉HRILDI₁₄₄) found in r08019 is indicated by a box. The Y₃₉C
5
6
7
8 substitution present in SIV DNA at wk 2 PI is also enclosed by a box. However,
9
10 this mutation was not detected in the rebounding virus following the CD8 α
11
12 depletion. The sequence corresponding to the SIVmacC8 *nef* deletion is
13 underlined. C) Short direct nucleotide repeats near the limits of the deleted
14
15 region in *nef* are underlined. These repeated stretches are 8 nucleotides long,
16
17 seven of which are identical in each repeat. The position of the nucleotides
18
19 relative to the SIVmac239 genome is indicated on top and the deleted aa region
20
21 is enclosed by a box. The *nef* deletion overlaps with the 3' long terminal repeat
22
23 U3 region, which spans nucleotides 9,452-9,978.
24
25
26
27
28
29
30
31

32 **Figure 7. Post-infection analysis of SIV-specific T-cell responses in r08019.**

33
34 We carried out an intracellular cytokine staining assay in PBMC from r08019 at
35
36 wk 3.4 PI. The stimuli consisted of pools of peptides spanning the entire Nef
37
38 protein or three segments of the Gag polyprotein. A peptide corresponding to the
39
40 Mamu-A*01-restricted Gag₁₈₁₋₁₈₉CM9 epitope was included as well. Reactivity to
41
42 each stimulus is shown based on the production of IFN- γ and/or TNF- α . CD8⁺
43
44 and CD4⁺ T-lymphocytes are shown in the top and bottom rows, respectively.
45
46
47
48
49
50

51 **Figure 8. Genome-wide deep sequencing of the SIVmac239 stock used for**
52 **the IR challenges.** Heat map illustration of the level of sequence variation
53
54 across the SIVmac239 genome detected from 454 deep sequencing. Plotted is
55
56
57
58
59
60


1
2
3 the percentage of amino acid diversity at each position across the genome with
4
5 the first amino acid of Gag located in the top left corner of the grid and the last
6
7 amino acid of Nef located in the bottom right corner. Completely conserved
8
9 codons are black and low-level variant residues (<10%) are colored light blue.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLE 1. Animal characteristics.


Exptl group	Animal ID	MHC-I alleles	Age (yrs) ¹	Gender
Group 1	r04132	<i>Mamu-B*08</i>	8.3	Female
	r07032	<i>Mamu-B*08</i>	5.3	Male
Group 2	r08019	<i>Mamu-A*01</i>	4.7	Female
	r01049	<i>Mamu-A*01</i>	11.7	Male
Group 3	r09037	<i>Mamu-B*08</i>	6.2	Female
	r09089	<i>Mamu-B*08</i>	5.8	Male

¹ Animal age at beginning of study.


A) Experimental layout




B) Vaccine-induced CD8⁺ T-cell responses in Group 1




C) Vaccine-induced CD8⁺ T-cell responses in Group 2



D) Memory phenotype of vaccine-induced CD8⁺ T-cells in Group 1




E) Memory phenotype of vaccine-induced CD8⁺ T-cells in Group 2



F) Rate of SIV acquisition


Animal ID	% of tetramer ⁺ CD8 ⁺ T-cells at wk 34 post rYF17D	Infecting IR exposure								
		1	2	3	4	5	6	7	8	9
r04132	0.4								X	
r07032	0.3		X							
r1049	0.9								X	
r08019	4.6									X

G) Viral loads




227x302mm (300 x 300 DPI)

A) Viral loads in Group 1 compared to historical SIVmac239-infected *Mamu-B*08** macaques




B) Viral loads in Group 2 compared to historical SIVmac239-infected *Mamu-A*01** macaques




57x20mm (300 x 300 DPI)


A) Layout of sequential lymphocyte depletions




B) Absolute CD8αβ+ T-cell counts




C) Absolute NK cell counts




D) Absolute CD8αα+ T-cell counts



E) Absolute CD4+ T-cell counts




F) Viral loads




144x125mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


A) Layout of CD8β depletion




B) Absolute CD8αβ⁺ T-cell counts




C) Absolute NK cell counts




D) Absolute CD8αα⁺ T-cell counts



E) Absolute CD4⁺ T-cell counts



F) Viral loads




142x147mm (300 x 300 DPI)


Distribution

FIGURE 5

A) Endpoint titers of anti-Ig antibodies in r04132




B) Endpoint titers of anti-Ig antibodies in r08019



128x115mm (300 x 300 DPI)

FIGURE 6

A) Scheme of viral sequencing analysis in monkey r08019



B) Alignment of predicted Nef amino acid sequences found in r08019

PBMC SIV DNA wk 2 PI	MGGATSMRRSRPFGDLRQRLLRARGETYGRLLGEVDDG	FSOSPGGLDKGLSSLSCGQKY	60
Plasma SIV RNA wk 38.4 PI	MGGATSMRRSRPFGDLRQRLLRARGETYGRLLGEVDDG	FSOSPGGLDKGLSSLSCGQKY	60
SIVmac239	MGGATSMRRSRPFGDLRQRLLRARGETYGRLLGEVDDG	FSOSPGGLDKGLSSLSCGQKY	60

PBMC SIV DNA wk 2 PI	NQQQYMNTPWRNPAEEREKLAYRKQNMDDIDEEDDDL	LVGVSVRPKVPVLRMTSYKLAIDMS	120
Plasma SIV RNA wk 38.4 PI	NQQQYMNTPWRNPAEEREKLAYRKQNMDDIDEEDDDL	LVGVSVRPKVPVLRMTSYKLAIDMS	120
SIVmac239	NQQQYMNTPWRNPAEEREKLAYRKQNMDDIDEEDDDL	LVGVSVRPKVPVLRMTSYKLAIDMS	120

PBMC SIV DNA wk 2 PI	HFIKEKGGLEGIYYSARR	YLEKEEGIIPOWQDYTS	174
Plasma SIV RNA wk 38.4 PI	HFIKEKGGLEGIYYSARR	YLEKEEGIIPOWQDYTS	174
SIVmac239	HFIKEKGGLEGIYYSARR	YLEKEEGIIPOWQDYTS	180

PBMC SIV DNA wk 2 PI	NVSDEAQEEDDEHYLMHPAQT	SQWDDPWGEVLAWKFDPTL	234
Plasma SIV RNA wk 38.4 PI	NVSDEAQEEDDEHYLMHPAQT	SQWDDPWGEVLAWKFDPTL	234
SIVmac239	NVSDEAQEEDDEHYLMHPAQT	SQWDDPWGEVLAWKFDPTL	240

PBMC SIV DNA wk 2 PI	EEEVRRRLTARGLLNADKKETR		257
Plasma SIV RNA wk 38.4 PI	EEEVRRRLTARGLLNADKKETR		257
SIVmac239	EEEVRRRLTARGLLNADKKETR		263

* Fully conserved residues

C) Short nucleotide direct repeats near the ends of the nef deletion

9,490 9,500 9,510 9,520


gcaagaagaacatagaatcttagacataacttagaaaag

A R R H R I L D I Y L E K

Deletion of aa 139-144

113x72mm (300 x 300 DPI)


FIGURE 7



65x24mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE 8



141x119mm (300 x 300 DPI)